Gynecologic oncology referral rates of adnexal masses suspicious for ovarian cancer in an academic health system: A cohort study.

A Anna Jo Bodurtha Smith (University of Pennsylvania, Philadelphia, PA) S Sarah Bell T Tessa Cook (University of Pennsylvania, Philadelphia, PA) S Shivan Mehta (Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA) C Charlie Chambers (University of Pennsylvania, Philadelphia, PA) H Hanna M. Zafar (University of Pennsylvania, Philadelphia, PA) L Lisa Jones L Lin Xu (Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.) J Justin E. Bekelman (Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA) A Anne Marie McCarthy (University of Pennsylvania, Philadelphia, PA) E Elizabeth A. Howell (University of Pennsylvania, Philadelphia, PA)

Abstract

5544 Background: Ovarian-Adnexal Reporting Data System (O-RADS) is an international lexicon and risk stratification tool. O-RADS 4 or 5 lesions are complex adnexal masses that a 10-90% risk of malignancy, and national guidelines recommend gynecologic oncology referral. Our objective was to examine patient, clinician, and imaging factors associated with referral to gynecologic oncology for complex adnexal masses. Methods: This retrospective cohort study was exempt from IRB review. We identified all patients with O-RADS 4 or 5 lesions on ultrasound (US) or MRI from July 1, 2020 to December 31, 2023. Our primary outcome was referral to gynecologic oncology. We gathered patient demographic data and ordering clinician characteristics from electronic health records. We performed descriptive statistics and multivariate logistic regression of patient demographics and ordering clinician characteristics associated with gynecologic oncology referral. Results: Our cohort included 373 patients with O-RADS 4 or 5 lesions and no prior gynecologic oncology care. The referral rate to gynecologic oncology was 68%, and referral within 30 days of abnormal imaging was 43%. Time from abnormal imaging to referral ranged from 0 to 407 days (mean 15.3, median 4 days). In multivariate analyses, the likelihood of referral to gynecologic oncology was higher among patients with repeat abnormal imaging compared to those with single instance of abnormal imaging (aOR 20.61, 95%CI 2.63-161.6), O-RADS 5 lesions compared to O-RADS 4 lesions (aOR 9.15, 95%CI 3.47-24.85) and detection on MRI compared to US (aOR 7.79, 95%CI 1.57-38.65). The likelihood of referral to gynecologic oncology was lower among non-white patients (aOR 0.24, 95%CI 0.08-0.76). There were no differences by Hispanic ethnicity, rurality, insurance, or language. Referral was higher among patients whose imaging was ordered by an internal medicine clinician (aOR 3.89, 95%CI 1.48-10.20) compared to ob/gyn. Conclusions: One-third of patients with complex adnexal masses were not referred to gynecologic oncology. Disparities in referral to gynecologic oncology for complex adnexal masses rates based on patient race and ordering clinician specialty highlight the need for system-based approaches including clinician education or automated referrals. Gynecologic oncology referral after O-RADS 4/5. Multivariate OR (95%CI) Postmenopausal (≥55 years) 1.89 (0.95-3.74) Race - White Reference - Black 0.57 (0.27-1.21) - Asian 1.03 (0.30-3.58) - Some other race 0.24 (0.08-0.76) Ordering specialty - Obstetrics/Gynecology Reference - Emergency Medicine 0.93 (0.33-2.62) - Internal Medicine 3.89 (1.48-10.20) - Family Medicine 1.62 (0.66-3.98) - Other specialty 0.87 (0.27-2.76) Has PCP 1.66 (0.81-3.42) O-RADS - 4 Reference - 5 9.15 (3.27-24.85) Imaging - MRI 7.79 (1.57-38.65) - US Reference Repeat abnormal imaging 20.61 (2.63-161.79)

Article Details

Volume / Issue Vol. 43, Issue 16_suppl
Published June 01, 2025
Pages 5544-5544
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (11)

A

Anna Jo Bodurtha Smith

University of Pennsylvania, Philadelphia, PA

S

Sarah Bell

T

Tessa Cook

University of Pennsylvania, Philadelphia, PA

S

Shivan Mehta

Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

C

Charlie Chambers

University of Pennsylvania, Philadelphia, PA

H

Hanna M. Zafar

University of Pennsylvania, Philadelphia, PA

L

Lisa Jones

L

Lin Xu

Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.

J

Justin E. Bekelman

Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

A

Anne Marie McCarthy

University of Pennsylvania, Philadelphia, PA

E

Elizabeth A. Howell

University of Pennsylvania, Philadelphia, PA